Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: A strong positive correlation between plasma apolipoprotein (apo) C-III and triglyceride concentrations has been invariably observed in human and animal studies. The hypertriglyceridemic effect of apo C-III has been conventionally explained by its extracellular roles in inhibiting lipolysis catalysed by lipoprotein lipase and attenuating triglyceride-rich lipoprotein clearance through receptor-dependent and/or independent mechanisms. However, recent experimental evidence suggests that apo C-III may also play an intracellular role in promoting hepatic triglyceride-rich lipoprotein production. RECENT FINDINGS: Kinetic studies with humans and genetically modified mice have shown that apo C-III is linked with increased production of triglyceride-rich lipoproteins, such as very-low-density lipoprotein 1 (VLDL1). Mutational studies on human apo C-III variants (originally identified in humans with hypotriglyceridemia or hyperalphalipoproteinemia) provide the structure-function analysis of human apo C-III, demonstrating that loss-of-function mutations within human apo C-III impair the assembly and secretion of triglyceride-rich VLDL1 under lipid-rich conditions. SUMMARY: The current review summarizes recent experimental evidence for an intrahepatic role of human apo C-III in promoting mobilization and utilization of triglyceride during VLDL1 assembly/secretion. Understanding mechanisms by which hepatic apo C-III expression is regulated under insulin resistance and diabetic conditions will lead to better and more rational strategies for the prevention and treatment of diabetic hypertriglyceridemia that is closely related to premature atherosclerosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experimental studies show that apoCIII enhances hepatic assembly and secretion of VLDL, and human kinetic studies have shown an association between apoCIII and VLDL production [47].”
In the citing paper
“Apo C-III is expressed both intestinally and hepatically, circulates with TG-rich lipoproteins, has net deleterious effects on lipoprotein metabolism58–63”
From Clinical review on triglycerides (2020) · cites this paper as [60]
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“fatty acids of adipocyte origin or released from hydrolysis of remnant lipoproteins), as well as endogenous de-novo lipogenesis (DNL), are the major substrate for hepatic triglyceride synthesis [13].”
BackgroundSelective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965 · cited 1×
“Second, the FoxO1 branch of the insulin signalling becomes insensitive to insulin, whereas the DNL (controlled by the SREBP-1c pathway) remains responsive [13,52].”
BackgroundAdiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820 · cited 1×
“2b), a hallmark for diabetic hypertriglyceridemia [54] that often occurs at the initial stage of insulin resistance [55].”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“On the contrary, loss-of-function mutations within the human APOC3 gene have been associated with hypotriglyceridemia [5], hyperalphalipoproteinemia [6], and cardioprotective lipid/lipoprotein profiles in the Old Order Amish population [7].”
BackgroundSacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · cited 1×
“VLDL or LDL containing apo C-III imposes a greater risk to cardiovascular complications [21].”
BackgroundApolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339 · cited 1×
“Unau 0957-9672 2012 Wolters Kluwer Health | Lippincott Williams & Wilk Negative regulators include peroxisome proliferator-activated receptor-a [35], peroxisome proliferator-activated receptor-g [36], farnesoid X receptor [37] and Rev-erba [38].”
BackgroundMaeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313 · cited 1×
“Unautho been observed in Apoc3-null mice [8].”
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309 · cited 3×
“Fourth, the dysregulated FoxO1 signalling is unable to attenuate MTP and apo C-III expression [41,47].”
BackgroundFoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice
Kamagate, A., Qu, S., Perdomo, G., Su, D., Kim, D. H., Slusher, S., Meseck, M., & Dong, H. H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32914 · Cited by 282 · cited 2×
“Fourth, the dysregulated FoxO1 signalling is unable to attenuate MTP and apo C-III expression [41,47].”
BackgroundOverproduction of VLDL 1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia
Adiels, M., Borén, J., Caslake, M. J., Stewart, P., Soro, A., Westerbacka, J., Wennberg, B., Olofsson, S.-O., Packard, C., & Taskinen, M.-R. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000172689.53992.25 · Cited by 269 · cited 1×
“But the situation in diabetic hypertriglyceridemia is different, in which both hyperglycemia and hyperinsulinemia contribute to overproduction of VLDL1 [50,51].”
BackgroundFarnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J.-C., Gonzalez, F. J., & Staels, B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00896-5 · Cited by 268 · cited 1×
“Unau 0957-9672 2012 Wolters Kluwer Health | Lippincott Williams & Wilk Negative regulators include peroxisome proliferator-activated receptor-a [35], peroxisome proliferator-activated receptor-g [36], farnesoid X receptor [37] and Rev-erba [38].”
BackgroundFoxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419992 · Cited by 260
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M. R. (1998) · Diabetes · doi:10.2337/diabetes.47.5.779 · Cited by 198 · cited 1×
“These scenarios combined well explain the restricted hepatic VLDL production under the short-term hyperinsulinemia with euglycemia in humans [48] and the acute glucoseinduced hyperinsulinemia in rats [49] (Fig.”
BackgroundChen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 184
Sundaram, M., Zhong, S., Khalil, M. B., Links, P. H., Zhao, Y., Iqbal, J., Hussain, M. M., Parks, R. J., Wang, Y., & Yao, Z. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m900346-jlr200 · Cited by 171
Self-citationCohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170 · cited 6×
“Sorensen LP, Andersen IR, Sondergaard E, et al. Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men.”
InfluentialCaron, S., Verrijken, A., Mertens, I., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.220723 · Cited by 162
Gordon, D. A., Wetterau, J. R., & Gregg, R. E. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)89054-6 · Cited by 154 · cited 1×
“The abetalipoproteinemia gene MTTP (encoding microsomal triglyceride-transfer protein or MTP) is indispensible for VLDL assembly/secretion [23].”
BackgroundSundaram, M., & Yao, Z. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-35 · Cited by 154 · cited 3×
“Secretion of hepatic triglyceride is achieved through assembling with the large, hydrophobic apoB-100 (4536 amino acids) to form a VLDL particle [12].”
BackgroundInfluentialSelf-citationMcFie, P. J., Banman, S. L., Kary, S., & Stone, S. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.256008 · Cited by 148 · cited 1×
“The DGAT2 enzyme, an endoplasmic reticulum membrane protein that catalyzes the last step in de-novo triglyceride synthesis, is enriched in mitochondrialassociated membranes and also present on cytosolic lipid droplets [14].”
BackgroundMendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145 · cited 1×
“The presence of apo C-III on triglyceride-rich lipoproteins counters apoE-mediated hepatic uptake [26], and the delayed clearance of triglyceride-rich lipoproteins can be a contributing factor to hypertriglyceridemia [27].”
BackgroundA Mouse Model with Features of Familial Combined Hyperlipidemia
Masucci-Magoulas, L., Goldberg, I. J., Bisgaier, C. L., Serajuddin, H., Francone, O. L., Breslow, J. L., & Tall, A. R. (1997) · Science · doi:10.1126/science.275.5298.391 · Cited by 142 · cited 1×
“High-level expression of human apo C-III in mice deficient in the LDL receptor has been created to serve as a model for familial combined hyperlipidemia [4].”
BackgroundLow-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease
Mendivil, C. O., Rimm, E. B., Furtado, J., Chiuve, S. E., & Sacks, F. M. (2011) · Circulation · doi:10.1161/circulationaha.111.056986 · Cited by 136 · cited 1×
“apo C-III also presents as a risk factor for coronary heart disease as compared to LDL devoid of apo C-III [28].”
BackgroundLee, H.-Y., Birkenfeld, A. L., Jornayvaz, F. R., Jurczak, M. J., Kanda, S., Popov, V., Frederick, D. W., Zhang, D., Guigni, B., Bharadwaj, K. G., et al. (2011) · Hepatology · doi:10.1002/hep.24571 · Cited by 134 · cited 1×
“Genetically modified mice [1], rabbits [2], or miniature pigs [3 & ] with high-level expression of human APOC3 show severe hypertriglyceridemia.”
BackgroundWang, Y., Tran, K., & Yao, Z. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27793 · Cited by 128 · cited 2×
“Rather, the activity of MTP is required for the mobilization of triglyceride and other neutral lipids into the endoplasmic reticulum/Golgi microsomes as substrates for VLDL assembly [19].”
BackgroundSelf-citationPhung, T. L., Roncone, A., Jensen, K. L. D. M., Sparks, C. E., & Sparks, J. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.49.30693 · Cited by 121 · cited 1×
“It is also known that acute insulin treatment leads to increased intracellular degradation of newly synthesized apoB (probably through the PI3K pathway) [46] as well as suppressed expression of apo C-III and MTP (through the FoxO1 pathway) [41,47].”
BackgroundDissociation between APOC3 variants, hepatic triglyceride content and insulin resistance
Kozlitina, J., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2011) · Hepatology · doi:10.1002/hep.24072 · Cited by 115
Tran, K., Thorne-Tjomsland, G., DeLong, C. J., Cui, Z., Shan, J., Burton, L., Jamieson, J. C., & Yao, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200249200 · Cited by 107 · cited 1×
“Recruitment of triglyceride during VLDL1 assembly is achieved through trafficking of nascent VLDL particles through the endoplasmic reticulum/Golgi compartments, a process that takes approximately 20–30 min [22].”
BackgroundSelf-citationQin, W., Sundaram, M., Wang, Y., Zhou, H., Zhong, S., Chang, C.-C., Manhas, S., Yao, E. F., Parks, R. J., McFie, P. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.203679 · Cited by 107
Self-citationMalmendier, C. L., Lontie, J., Delcroix, C., Dubois, D. Y., Magot, T., & Roy, L. D. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90075-0 · Cited by 94 · cited 1×
“fibrate [39] and pioglitazone [36]) have been used to attenuate apo C-III expression and thus lowering plasma triglyceride.”
MethodGill, J. M. R., Brown, J. C., Bedford, D. K., Wright, D. M., Cooney, J., Hughes, D. A., Packard, C. J., & CASLAKE, M. J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.04.022 · Cited by 88 · cited 1×
“But the situation in diabetic hypertriglyceridemia is different, in which both hyperglycemia and hyperinsulinemia contribute to overproduction of VLDL1 [50,51].”
BackgroundStructure and Dynamics of Human Apolipoprotein CIII
Gangabadage, C. S., Zdunek, J., Tessari, M., Nilsson, S., Olivecrona, G., & Wijmenga, S. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800756200 · Cited by 88 · cited 1×
“The NMR structure of apoC3 in an SDS micelle was composed of six helices labelled in h1 to h6 [34].”
BackgroundChirieac, D. V., Chirieac, L. R., Corsetti, J. P., Cianci, J., Sparks, C. E., & Sparks, J. D. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.5.e1003 · Cited by 88 · cited 1×
“These scenarios combined well explain the restricted hepatic VLDL production under the short-term hyperinsulinemia with euglycemia in humans [48] and the acute glucoseinduced hyperinsulinemia in rats [49] (Fig.”
BackgroundCaviglia, J. M., Gayet, C., Ota, T., Hernandez-Ono, A., Conlon, D. M., Jiang, H., Fisher, E. A., & Ginsberg, H. N. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m016931 · Cited by 87 · cited 1×
“Different fatty acid species exert different effects on VLDL assembly/secretion [17].”
BackgroundOrphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter
Coste, H., & Rodrı́guez, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203421200 · Cited by 83 · cited 3×
“Unau 0957-9672 2012 Wolters Kluwer Health | Lippincott Williams & Wilk Negative regulators include peroxisome proliferator-activated receptor-a [35], peroxisome proliferator-activated receptor-g [36], farnesoid X receptor [37] and Rev-erba [38].”
Backgroundvon Eckardstein, A., Holz, H., Sandkamp, M., Weng, W., Funke, H., & Assmann, G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115190 · Cited by 81 · cited 2×
“On the contrary, loss-of-function mutations within the human APOC3 gene have been associated with hypotriglyceridemia [5], hyperalphalipoproteinemia [6], and cardioprotective lipid/lipoprotein profiles in the Old Order Amish population [7].”
BackgroundMetabolism of VLDL and LDL subclasses
Griffin, B. A., & Packard, C. J. (1994) · Current Opinion in Lipidology · doi:10.1097/00041433-199405030-00007 · Cited by 76 · cited 1×
“In-vivo human kinetic studies suggest that the large VLDL1 particles are catabolized in the circulation into the atherogenic, small and dense LDL [20].”
BackgroundGinsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64 · cited 2×
“As a major plasma protein (10 mg/dl), apo C-III is known to play an extracelluar role in inhibiting lipolysis and clearance of triglyceride-rich lipoproteins leading to hypertriglyceridemia [9].”
BackgroundLowering apolipoprotein CIII delays onset of type 1 diabetes
Holmberg, R., Refai, E., Höög, A., Crooke, R. M., Graham, M., Olivecrona, G., Berggren, P.-O., & Juntti-Berggren, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019553108 · Cited by 59 · cited 1×
“Increased plasma apo C-III concentration occurs in type I diabetic patients, and lowering apo C-III in a rat diabetic model has been shown to delay the onset of diabetes [29].”
BackgroundSundaram, M., Zhong, S., Khalil, M. B., Zhou, H., Jiang, Z. G., Zhao, Y., Iqbal, J., Hussain, M. M., Figeys, D., Wang, Y., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005108 · Cited by 59
Self-citationBasal and Insulin Mediated VLDL-Triglyceride Kinetics in Type 2 Diabetic Men
Sørensen, L. P., Andersen, I. R., Søndergaard, E., Gormsen, L. C., Schmitz, O., Christiansen, J. S., & Nielsen, S. (2011) · Diabetes · doi:10.2337/db10-0564 · Cited by 51 · cited 1×
“Thus, the intracellular role of apo C-III in VLDL1 assembly provides a rational explanation for diabetic hypertriglyceridemia, in which contribution from the decrease in VLDL-triglyceride clearance appears to be marginal [56].”
BackgroundWei, J., Ouyang, H., Wang, Y., Pang, D., Cong, N. X., Wang, T., Leng, B., Li, D., Li, X., Wu, R., et al. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08401.x · Cited by 50
Self-citationTran, K., Wang, Y., DeLong, C. J., Cui, Z., & Yao, Z. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908971199 · Cited by 49 · cited 1×
“In addition to that of cytosolic triglyceride, hydrolysis of phospholipids, catalysed by phospholipases such as iPLA2 (Ca 2þ-independent phospholipase A2) [16], may also provide fatty acyl chains VLDL-triglyceride synthesis.”
BackgroundSelf-citationSørensen, L. P., Søndergaard, E., Nellemann, B., Christiansen, J. S., Gormsen, L. C., & Nielsen, S. (2011) · Diabetes · doi:10.2337/db11-0040 · Cited by 44 · cited 1×
“2b), a hallmark for diabetic hypertriglyceridemia [54] that often occurs at the initial stage of insulin resistance [55].”
BackgroundShin, M., & Krauss, R. M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.025 · Cited by 42 · cited 1×
“Increased apo C-III content has been observed in the atherogenic, small and dense LDL particles [25].”
BackgroundLiu, H., Labeur, C., Xu, C.-F., Ferrell, R., Lins, L., Brasseur, R., Rosseneu, M., Weiss, K. M., Humphries, S. E., & Talmud, P. J. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31969-6 · Cited by 41
Ding, Y., Wang, Y., Zhu, H., Fan, J., Yu, L., Liu, C., & Liu, E. (2010) · Transgenic Research · doi:10.1007/s11248-010-9467-5 · Cited by 40 · cited 1×
“Genetically modified mice [1], rabbits [2], or miniature pigs [3 & ] with high-level expression of human APOC3 show severe hypertriglyceridemia.”
BackgroundSelf-citationSentinelli, F., Romeo, S., Maglio, C., Incani, M., Burza, M. A., Scano, F., Coccia, F., Cossu, E., Leonetti, F., & Baroni, M. G. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-93 · Cited by 40
Moon, B. C., Hernandez-Ono, A., Stiles, B., Wu, H., & Ginsberg, H. N. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241356 · Cited by 40 · cited 2×
“Acute exposure of cells with insulin is known to suppress effectively secretion of apoB and triglyceride, despite increased triglyceride synthesis [45].”
BackgroundTran, K. T., Sun, F., Cui, Z., Thorne‐Tjomsland, G., Germain, C. S., Lapierre, L. R., McLeod, R. S., Jamieson, J. C., & Yao, Z. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.03.018 · Cited by 33 · cited 1×
“As well, triglyceride synthesized from different fatty acid species can be differentially utilized for VLDL assembly/secretion [18], and the selectivity in utilizing triglyceride derived from different fatty acids is likely attributable to compartmentalization of newly synthesized triglyceride.”
BackgroundSelf-citationBrown, A.-M., Wiggins, D. K., & Gibbons, G. F. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.2.321 · Cited by 25 · cited 1×
“Previous studies showed that bulk triglyceride incorporation into VLDL was enhanced by glucose in cultured hepatocytes [43], an ex-vivo model system in which the effect of insulin is less dominant.”
BackgroundLiu, Y., Manchekar, M., Sun, Z., Richardson, P. E., & Dashti, N. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005371 · Cited by 20 · cited 1×
“Accumulating experimental evidence suggests the activity of MTP is not essential for the initial lipidation of apoB-100 during translation and translocation of apoB-100 across the endoplasmic reticulum membranes [24].”
BackgroundWu, K., Cappel, D. A., Martinez, M., & Stafford, J. M. (2010) · Endocrinology · doi:10.1210/en.2010-0204 · Cited by 19 · cited 1×
“Thus under normal physiological conditions, the action of glucose on VLDL production would be overcome rapidly by insulin [44].”
BackgroundBernard, N., Girouard, J., Forest, J., & Giguère, Y. (2007) · Journal of Human Genetics · doi:10.1007/s10038-006-0106-1 · Cited by 18 · cited 1×
“Moreover, a potential role of apo C-III in gestational preeclampsia [30] and gestational hypertension [31] has been suggested in clinical studies.”
BackgroundElevated Ratio of Maternal Plasma ApoCIII to ApoCII in Preeclampsia
Flood-Nichols, S. K., Stallings, J. D., Gotkin, J. L., Tinnemore, D., Napolitano, P. G., & Ippolito, D. L. (2011) · Reproductive Sciences · doi:10.1177/1933719110390390 · Cited by 11 · cited 1×
“Moreover, a potential role of apo C-III in gestational preeclampsia [30] and gestational hypertension [31] has been suggested in clinical studies.”
BackgroundRegional disposal of intravenously infused glucose during prolonged hyperglycemia–hyperinsulinemia
Sidossis, L. S., Mittendorfer, B., Walser, E., & Wolfe, R. R. (1999) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(99)00043-1 · Cited by 7 · cited 1×
“Moreover, increased glucose uptake exacerbates the detrimental effects of glucose to cellular metabolism [53] including augmented apo C-III expression.”
BackgroundEthnicity differences in plasma apoC-III levels between African American and Caucasian youths
Lee, J., Hong, H.-R., & Kang, H. (2011) · World Journal of Pediatrics · doi:10.1007/s12519-011-0266-8 · Cited by 4 · cited 1×
“Difference in plasma apo C-III concentrations have been noted between African– Americans and Caucasians [60].”
Background
Cited by
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Sugar consumption, metabolic disease and obesity: The state of the controversy
Stanhope, K. L. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1084990 · Cited by 739
“Hepatic insulin resistance may also indirectly increase VLDL production and secretion by 1) increasing apolipoprotein B (apoB) availability (42, 43), the protein backbone of VLDL; 2) up-regulating microsomal triglyceride-transfer protein expression (41), which catalyzes the assembly of TG and apoB into VLDL; and 3) in…”
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
“In a series of publications, Yao and coworkers have unraveled an intracellular role of apo-CIII in promoting hepatic VLDL1 secretion [144,149,150].”
Background
Metadata
- Authors
- Yao, Z., & Wang, Y.
- Affiliations
- University of Ottawa (CA)
- Corresponding author
- Yao, Zemin
- Venue
- Current Opinion in Lipidology
- Published
- 2012-06
- Volume
- 23
- Issue
- 3
- Pages
- 206-212
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2041953515
- Cited by
- 100
- References
- 60
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 11 · 2016: 8 · 2015: 12 · 2014: 10 · 2013: 7 · 2012: 2
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein C-III, hypertriglyceridemia, hypotriglyceridemia, hyperalphalipoproteinemia, insulin resistance, diabetes mellitus, triglyceride mobilization, lipoprotein lipase
- MeSH terms
- Animals, Gene Expression Regulation, Homeostasis, Humans, Liver, Triglycerides, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.